Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the target of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 14,245 shares, a drop of 50.6% from the July 30th total of 28,818 shares. Based on an average daily volume of 345,411 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Chugai Pharmaceutical Price Performance

Shares of CHGCY stock traded up $0.16 on Friday, hitting $21.82. The company’s stock had a trading volume of 117,081 shares, compared to its average volume of 208,202. The stock has a market capitalization of $71.82 billion, a price-to-earnings ratio of 23.72 and a beta of 0.60. Chugai Pharmaceutical has a fifty-two week low of $20.43 and a fifty-two week high of $34.84. The firm’s fifty day moving average price is $22.25 and its 200-day moving average price is $25.43.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The firm had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Analysts predict that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.